A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)

Novartis Investigative Site, Leuven

Novartis Investigative Site, Parkville

Novartis Investigative Site, Christchurch

Novartis Investigative Site, Caen

Novartis Investigative Site, Dijon

Duke University Medical Center, Durham

Medical University of South Carolina Oncology, Charleston

Georgia Health Sciences University Medical College of Georgia, Augusta

Vanderbilt University Medical Center Vanderbilt Clinic - Oncology, Nashville

Novartis Investigative Site, Essen-Werden

Indiana University, Indianapolis

Novartis Investigative Site, Duisburg

Novartis Investigative Site, Cologne

Medical College of Wisconsin Oncology, Milwaukee

Mayo Clinic - Rochester Hematology/Oncology Dept., Rochester

Novartis Investigative Site, Reggio Calabria

Cedars Sinai Medical Center, Los Angeles

University of California at Los Angeles, Los Angeles

Novartis Investigative Site, Singapore

Novartis Investigative Site, Saint Petersburg

Novartis Investigative Site, ChelyabinskChemo

Novartis Investigative Site, Haifa

Novartis Investigative Site, Ramat Gan

Northwestern University Oncology, Chicago

Massachusetts General Hospital, Boston

Dana-Farber Cancer Institute Dana-Farber Cancer Institute, Boston

Mary Babb Randolph Cancer Center, Morgantown

Novartis Investigative Site, Curitiba

Novartis Investigative Site, Rio de Janeiro

Novartis Investigative Site, Toronto

Novartis Investigative Site, Lille

Novartis Investigative Site, Amsterdam

Novartis Investigative Site, Rotterdam

Novartis Investigative Site, Krakow

Novartis Investigative Site, Wroclaw